Standard

Опыт успешного применения аутологичной трансплантации стволовых гемопоэтических клеток у пациенток с неблагоприятным прогнозом течения диффузной формы системной склеродермии. / Mazurov, Vadim I.; Maslyanskiy, Alexey L.; Zotkina, Kira E.; Benevolenskaya, Stanislava S.; Motorin, Dmitry V.; Zaritskiy, Andrey Yu; Vasilenko, Elizaveta A.; Vasilenko, Alexey A.; Titova, Anna M.

в: Nauchno-Prakticheskaya Revmatologiya, Том 60, № 3, 10.07.2022, стр. 381-387.

Результаты исследований: Научные публикации в периодических изданияхстатьяРецензирование

Harvard

APA

Vancouver

Author

Mazurov, Vadim I. ; Maslyanskiy, Alexey L. ; Zotkina, Kira E. ; Benevolenskaya, Stanislava S. ; Motorin, Dmitry V. ; Zaritskiy, Andrey Yu ; Vasilenko, Elizaveta A. ; Vasilenko, Alexey A. ; Titova, Anna M. / Опыт успешного применения аутологичной трансплантации стволовых гемопоэтических клеток у пациенток с неблагоприятным прогнозом течения диффузной формы системной склеродермии. в: Nauchno-Prakticheskaya Revmatologiya. 2022 ; Том 60, № 3. стр. 381-387.

BibTeX

@article{ed7c2716aa5545408815b15f4b5ac608,
title = "Опыт успешного применения аутологичной трансплантации стволовых гемопоэтических клеток у пациенток с неблагоприятным прогнозом течения диффузной формы системной склеродермии",
abstract = "One of the methods of treating severe forms of systemic scleroderma is hematopoietic stem-cell autotransplantation (auto-HSCT). The article describes two clinical cases of auto-HSCT followed by rituximab (RTM) therapy in patients with diffuse systemic scleroderma with progressive interstitial lung disease (ILD), high immunological activity, high skin score, and an unfavorable prognosis. The assessment of the course of these diseases was carried out in the course of dynamic observation of patients for 10–11 years. In all cases, auto-HSCT followed by RTM made it possible to achieve remission / low activity, as well as to stabilize the progressive of ILD.",
keywords = "autologous bone marrow transplantation, interstitial lung disease, systemic scleroderma, autologous bone marrow transplantation, interstitial lung disease, systemic scleroderma",
author = "Mazurov, {Vadim I.} and Maslyanskiy, {Alexey L.} and Zotkina, {Kira E.} and Benevolenskaya, {Stanislava S.} and Motorin, {Dmitry V.} and Zaritskiy, {Andrey Yu} and Vasilenko, {Elizaveta A.} and Vasilenko, {Alexey A.} and Titova, {Anna M.}",
note = "Publisher Copyright: {\textcopyright} 2022 Ima-Press Publishing House. All rights reserved.",
year = "2022",
month = jul,
day = "10",
doi = "10.47360/1995-4484-2022-381-387",
language = "русский",
volume = "60",
pages = "381--387",
journal = "НАУЧНО-ПРАКТИЧЕСКАЯ РЕВМАТОЛОГИЯ",
issn = "1995-4484",
publisher = "ИМА-Пресс",
number = "3",

}

RIS

TY - JOUR

T1 - Опыт успешного применения аутологичной трансплантации стволовых гемопоэтических клеток у пациенток с неблагоприятным прогнозом течения диффузной формы системной склеродермии

AU - Mazurov, Vadim I.

AU - Maslyanskiy, Alexey L.

AU - Zotkina, Kira E.

AU - Benevolenskaya, Stanislava S.

AU - Motorin, Dmitry V.

AU - Zaritskiy, Andrey Yu

AU - Vasilenko, Elizaveta A.

AU - Vasilenko, Alexey A.

AU - Titova, Anna M.

N1 - Publisher Copyright: © 2022 Ima-Press Publishing House. All rights reserved.

PY - 2022/7/10

Y1 - 2022/7/10

N2 - One of the methods of treating severe forms of systemic scleroderma is hematopoietic stem-cell autotransplantation (auto-HSCT). The article describes two clinical cases of auto-HSCT followed by rituximab (RTM) therapy in patients with diffuse systemic scleroderma with progressive interstitial lung disease (ILD), high immunological activity, high skin score, and an unfavorable prognosis. The assessment of the course of these diseases was carried out in the course of dynamic observation of patients for 10–11 years. In all cases, auto-HSCT followed by RTM made it possible to achieve remission / low activity, as well as to stabilize the progressive of ILD.

AB - One of the methods of treating severe forms of systemic scleroderma is hematopoietic stem-cell autotransplantation (auto-HSCT). The article describes two clinical cases of auto-HSCT followed by rituximab (RTM) therapy in patients with diffuse systemic scleroderma with progressive interstitial lung disease (ILD), high immunological activity, high skin score, and an unfavorable prognosis. The assessment of the course of these diseases was carried out in the course of dynamic observation of patients for 10–11 years. In all cases, auto-HSCT followed by RTM made it possible to achieve remission / low activity, as well as to stabilize the progressive of ILD.

KW - autologous bone marrow transplantation

KW - interstitial lung disease

KW - systemic scleroderma

KW - autologous bone marrow transplantation

KW - interstitial lung disease

KW - systemic scleroderma

UR - http://www.scopus.com/inward/record.url?scp=85135241784&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/b66224c9-e7f3-3c69-aa5b-935e99899bb8/

U2 - 10.47360/1995-4484-2022-381-387

DO - 10.47360/1995-4484-2022-381-387

M3 - статья

VL - 60

SP - 381

EP - 387

JO - НАУЧНО-ПРАКТИЧЕСКАЯ РЕВМАТОЛОГИЯ

JF - НАУЧНО-ПРАКТИЧЕСКАЯ РЕВМАТОЛОГИЯ

SN - 1995-4484

IS - 3

ER -

ID: 100703938